1
|
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist.
|
J Exp Med
|
2004
|
3.88
|
2
|
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation.
|
FASEB J
|
2005
|
3.61
|
3
|
Bone morphogenetic proteins stimulate angiogenesis through osteoblast-derived vascular endothelial growth factor A.
|
Endocrinology
|
2002
|
2.49
|
4
|
Atypical fractures and bisphosphonate therapy: a cohort study of patients with femoral fracture with radiographic adjudication of fracture site and features.
|
Bone
|
2010
|
2.21
|
5
|
Bone mineral density in sclerosteosis; affected individuals and gene carriers.
|
J Clin Endocrinol Metab
|
2005
|
2.05
|
6
|
SOST/sclerostin, an osteocyte-derived negative regulator of bone formation.
|
Cytokine Growth Factor Rev
|
2005
|
1.88
|
7
|
Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation.
|
J Bone Miner Res
|
2007
|
1.76
|
8
|
Atypical fractures of the femur and bisphosphonate therapy: A systematic review of case/case series studies.
|
Bone
|
2010
|
1.68
|
9
|
Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer.
|
Cancer Res
|
2007
|
1.63
|
10
|
BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo.
|
Am J Pathol
|
2007
|
1.58
|
11
|
Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer.
|
Eur J Nucl Med Mol Imaging
|
2004
|
1.42
|
12
|
Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: clues to the mechanism of increased bone fragility.
|
J Bone Miner Res
|
2009
|
1.41
|
13
|
Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis.
|
Clin Pharmacokinet
|
2005
|
1.37
|
14
|
Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo.
|
Cancer Res
|
2005
|
1.33
|
15
|
Prolonged bisphosphonate release after treatment in children.
|
N Engl J Med
|
2007
|
1.32
|
16
|
Bone material strength as measured by microindentation in vivo is decreased in patients with fragility fractures independently of bone mineral density.
|
J Clin Endocrinol Metab
|
2015
|
1.22
|
17
|
Peroxisome proliferator-activated receptor gamma (PPARgamma ) as a molecular target for the soy phytoestrogen genistein.
|
J Biol Chem
|
2002
|
1.21
|
18
|
Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
|
J Med Chem
|
2005
|
1.12
|
19
|
Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
|
J Bone Miner Res
|
2011
|
1.11
|
20
|
Dissociation of angiogenesis and osteoclastogenesis during endochondral bone formation in neonatal mice.
|
J Bone Miner Res
|
2002
|
1.06
|
21
|
Van Buchem disease: clinical, biochemical, and densitometric features of patients and disease carriers.
|
J Bone Miner Res
|
2013
|
1.06
|
22
|
Joint Official Positions of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX(®). Executive Summary of the 2010 Position Development Conference on Interpretation and use of FRAX® in clinical practice.
|
J Clin Densitom
|
2011
|
1.00
|
23
|
Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover.
|
Bone
|
2012
|
0.93
|
24
|
Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
|
J Bone Miner Res
|
2005
|
0.92
|
25
|
Strontium-89 (Metastron) and the bisphosphonate olpadronate reduce the incidence of spinal cord compression in patients with hormone-refractory prostate cancer metastatic to the skeleton.
|
Eur J Nucl Med Mol Imaging
|
2002
|
0.91
|
26
|
Inhibition of bone resorption and growth of breast cancer in the bone microenvironment.
|
Bone
|
2008
|
0.90
|
27
|
Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
|
Bone
|
2012
|
0.86
|
28
|
Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension.
|
J Bone Miner Res
|
2002
|
0.86
|
29
|
Short term whole body retention in relation to rate of bone resorption and cartilage degradation after intravenous bisphosphonate (pamidronate) in rheumatoid arthritis.
|
J Rheumatol
|
2004
|
0.86
|
30
|
SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development.
|
Dev Dyn
|
2007
|
0.84
|
31
|
Normal growth and muscle dysfunction in X-linked hypophosphatemic rickets associated with a novel mutation in the PHEX gene.
|
J Clin Endocrinol Metab
|
2008
|
0.83
|
32
|
Increased circulating levels of FGF23: an adaptive response in primary hyperparathyroidism?
|
Eur J Endocrinol
|
2011
|
0.82
|
33
|
Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis.
|
Drugs
|
2015
|
0.81
|
34
|
Medical treatment of hypercalcaemia.
|
Hormones (Athens)
|
2009
|
0.81
|
35
|
Relationships between pharmacokinetics and rate of bone turnover after intravenous bisphosphonate (olpadronate) in patients with Paget's disease of bone.
|
J Bone Miner Res
|
2003
|
0.81
|
36
|
Low-energy fractures of the humeral shaft and bisphosphonate use.
|
J Bone Miner Res
|
2012
|
0.80
|
37
|
Glucocorticoids are not always deleterious for bone.
|
J Bone Miner Res
|
2010
|
0.80
|
38
|
Osteoporosis and bone marrow mastocytosis: dissociation of skeletal responses and mast cell activity during long-term bisphosphonate therapy.
|
J Bone Miner Res
|
2002
|
0.79
|
39
|
No effect of rosuvastatin in the zoledronate-induced acute-phase response.
|
Calcif Tissue Int
|
2011
|
0.79
|
40
|
Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn's disease.
|
Osteoporos Int
|
2005
|
0.78
|
41
|
Paget's disease of bone in The Netherlands: a population-based radiological and biochemical survey--the Rotterdam Study.
|
J Bone Miner Res
|
2004
|
0.78
|
42
|
Severe hypophosphatemic osteomalacia in hormone-refractory prostate cancer metastatic to the skeleton: natural history and pitfalls in management.
|
Bone
|
2004
|
0.77
|
43
|
Determinants of induction and duration of remission of Paget's disease of bone after bisphosphonate (olpadronate) therapy.
|
Bone
|
2003
|
0.76
|
44
|
Bone diseases: bisphosphonates in osteoporosis--beyond 5 years.
|
Nat Rev Rheumatol
|
2013
|
0.76
|
45
|
In Memoriam: Olav Bijvoet 1928–2014.
|
Bone
|
2014
|
0.75
|